Business Context and Reporting Period
This Form 8-K filing by Molina Healthcare, Inc. reports corporate governance changes effective November 6, 2017, with the earliest event date of November 2, 2017. The filing addresses the resignation of a long-serving director and the concurrent appointment of the company's new President and Chief Executive Officer to the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a specific compensatory arrangement for advisory services.
- Advisory Compensation: Approximately $150,000 expected to be paid to the retiring director for advisory services through May 2018.
Material Changes
The primary material change is the composition of the Board of Directors:
- Resignation: Frank E. Murray, M.D., resigned from the Board effective November 6, 2017, citing personal reasons. He was a Class I director and member of the Corporate Governance and Nominating Committee and the Compliance and Quality Committee.
- Appointment: Joseph M. Zubretsky was elected as a Class I director effective November 6, 2017, to fill the vacancy. This appointment coincides with his start date as President and Chief Executive Officer.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It notes that Dr. Murray's resignation is not the result of any disagreement with the Company regarding operations, policies, or practices. The Board has engaged Dr. Murray as a consultant to provide advisory services for the remainder of his foregone term (through May 2018). Details regarding Mr. Zubretsky's employment agreement were previously disclosed in an October 10, 2017 Form 8-K.
Investor Verification Checklist
- Verify the terms of the employment agreement for Joseph M. Zubretsky referenced in the October 10, 2017 Form 8-K.
- Confirm the specific scope of advisory services Dr. Murray will provide as a consultant.
- Review the Company's 2018 proxy statement for the upcoming annual meeting where Mr. Zubretsky's director term will expire.